Progestagens for pain symptoms associated with endometriosis
In individuals with endometriosis, oral progestagens compared with placebo likely reduce overall pain and dysmenorrhoea and may reduce pelvic pain. Compared with other hormonal suppression strategies, the evidence is less certain due to the small number of studies for each comparison and outcome. Despite such limitations, this update provides a comprehensive overview and valuable insights on progestagen treatment for endometriosis, emphasising the nuanced balance between efficacy, adverse effects, and patient satisfaction.
Authors
- Sari Kives (ORCID: https://orcid.org/0000-0002-6914-7399)
- Jeppe Bennekou Schroll (ORCID: https://orcid.org/0000-0002-1776-0562)
- Ai-Lien Le (ORCID: https://orcid.org/0000-0001-8598-4317)
- Hanna R. Goldberg (ORCID: https://orcid.org/0000-0001-7198-0868)
- Emilie Kowalczewski (ORCID: https://orcid.org/0000-0002-3786-1395)
- Innie Chen (ORCID: https://orcid.org/0000-0002-6389-4617)
- Andrew Zakhari (ORCID: https://orcid.org/0000-0003-4575-0393)
- Abdul Jamil Choudhry (ORCID: https://orcid.org/0000-0001-9197-1512)
- Dong Bach Nguyen (ORCID: https://orcid.org/0000-0002-1967-5548)
Institutions
- St. Michael's Hospital (CA)
- University of Ottawa (CA)
- University of Southern Denmark (DK)
- Ottawa Hospital (CA)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Cochrane (DK)
- St Michaels Hospital (GB)
- Ottawa Hospital Research Institute (CA)
- McGill University (CA)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1002/14651858.cd002122.pub3
- Primary Topic
- Endometriosis Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00